DK4021487T3 - Antigene peptider til forebyggelse og behandling af b-celle malignitet - Google Patents
Antigene peptider til forebyggelse og behandling af b-celle malignitet Download PDFInfo
- Publication number
- DK4021487T3 DK4021487T3 DK20804279.6T DK20804279T DK4021487T3 DK 4021487 T3 DK4021487 T3 DK 4021487T3 DK 20804279 T DK20804279 T DK 20804279T DK 4021487 T3 DK4021487 T3 DK 4021487T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- antigenic peptides
- cell malignancy
- malignancy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000036210 malignancy Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306475 | 2019-11-15 | ||
| EP2020079257 | 2020-10-16 | ||
| PCT/EP2020/082101 WO2021094562A2 (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for prevention and treatment of b-cell malignancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4021487T3 true DK4021487T3 (da) | 2024-02-12 |
Family
ID=75911928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20804279.6T DK4021487T3 (da) | 2019-11-15 | 2020-11-13 | Antigene peptider til forebyggelse og behandling af b-celle malignitet |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11759508B2 (da) |
| EP (2) | EP4357356A2 (da) |
| JP (1) | JP2023501204A (da) |
| CN (1) | CN114746112A (da) |
| AU (1) | AU2020384926A1 (da) |
| BR (1) | BR112022009100A2 (da) |
| CA (1) | CA3153470A1 (da) |
| DK (1) | DK4021487T3 (da) |
| FI (1) | FI4021487T3 (da) |
| HR (1) | HRP20240116T1 (da) |
| LT (1) | LT4021487T (da) |
| MX (1) | MX2022005704A (da) |
| PL (1) | PL4021487T3 (da) |
| RS (1) | RS65262B1 (da) |
| SI (1) | SI4021487T1 (da) |
| WO (1) | WO2021094562A2 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110022893B (zh) | 2016-10-07 | 2023-12-29 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| US11712465B2 (en) | 2016-10-07 | 2023-08-01 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| WO2023167213A1 (ja) * | 2022-03-01 | 2023-09-07 | ｂｉｔＢｉｏｍｅ株式会社 | アミノ酸残基配列を同定するための方法，プログラム及び記録媒体 |
| KR20240017325A (ko) * | 2022-07-29 | 2024-02-07 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| BR0009163A (pt) | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vacina |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| US7812116B2 (en) * | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| EP2119726B2 (en) | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2017184590A1 (en) * | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
| CN106008695A (zh) * | 2016-06-19 | 2016-10-12 | 苏州普罗达生物科技有限公司 | 一种关于cd19免疫原多肽及其用途 |
| JP7382310B2 (ja) * | 2017-09-06 | 2023-11-16 | カリフォルニア インスティチュート オブ テクノロジー | シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ） |
| KR20200067862A (ko) * | 2017-10-09 | 2020-06-12 | 엔터롬 에스.에이. | 종양-관련된 항원 에피토프의 미생물 서열 변이체 |
| HUE060791T2 (hu) * | 2018-04-11 | 2023-04-28 | Enterome S A | Antigén peptidek rák megelõzésére és kezelésére |
| WO2020072700A1 (en) * | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
-
2020
- 2020-11-13 HR HRP20240116TT patent/HRP20240116T1/hr unknown
- 2020-11-13 FI FIEP20804279.6T patent/FI4021487T3/fi active
- 2020-11-13 RS RS20240132A patent/RS65262B1/sr unknown
- 2020-11-13 EP EP23220228.3A patent/EP4357356A2/en active Pending
- 2020-11-13 CA CA3153470A patent/CA3153470A1/en active Pending
- 2020-11-13 JP JP2022525171A patent/JP2023501204A/ja active Pending
- 2020-11-13 BR BR112022009100A patent/BR112022009100A2/pt unknown
- 2020-11-13 WO PCT/EP2020/082101 patent/WO2021094562A2/en active Application Filing
- 2020-11-13 MX MX2022005704A patent/MX2022005704A/es unknown
- 2020-11-13 LT LTEPPCT/EP2020/082101T patent/LT4021487T/lt unknown
- 2020-11-13 CN CN202080083161.5A patent/CN114746112A/zh active Pending
- 2020-11-13 AU AU2020384926A patent/AU2020384926A1/en active Pending
- 2020-11-13 SI SI202030352T patent/SI4021487T1/sl unknown
- 2020-11-13 EP EP20804279.6A patent/EP4021487B1/en active Active
- 2020-11-13 PL PL20804279.6T patent/PL4021487T3/pl unknown
- 2020-11-13 DK DK20804279.6T patent/DK4021487T3/da active
-
2022
- 2022-05-02 US US17/734,694 patent/US11759508B2/en active Active
-
2023
- 2023-07-19 US US18/354,966 patent/US20240033335A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI4021487T3 (fi) | 2024-02-06 |
| HRP20240116T1 (hr) | 2024-04-12 |
| US11759508B2 (en) | 2023-09-19 |
| AU2020384926A1 (en) | 2022-04-28 |
| WO2021094562A2 (en) | 2021-05-20 |
| MX2022005704A (es) | 2022-06-08 |
| EP4021487B1 (en) | 2023-12-27 |
| US20240033335A1 (en) | 2024-02-01 |
| EP4357356A2 (en) | 2024-04-24 |
| BR112022009100A2 (pt) | 2022-07-26 |
| RS65262B1 (sr) | 2024-03-29 |
| LT4021487T (lt) | 2024-02-12 |
| PL4021487T3 (pl) | 2024-04-15 |
| EP4021487A2 (en) | 2022-07-06 |
| CN114746112A (zh) | 2022-07-12 |
| US20220323561A1 (en) | 2022-10-13 |
| JP2023501204A (ja) | 2023-01-18 |
| WO2021094562A3 (en) | 2021-09-30 |
| CA3153470A1 (en) | 2021-05-20 |
| SI4021487T1 (sl) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4021487T3 (da) | Antigene peptider til forebyggelse og behandling af b-celle malignitet | |
| DK3773689T3 (da) | Antigene peptider til forebyggelse og behandling af kræft | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3504210T3 (da) | 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion | |
| ZA202007649B (en) | Virus and antigen purification and conjugation | |
| SG11201810728UA (en) | Leg massager | |
| IL280720A (en) | Antigen binding molecule anti-CD137 and use thereof | |
| DK3388075T3 (da) | Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer | |
| IL280140A (en) | Antigen purification method | |
| SG11202011170YA (en) | Antibodies against lif and dosage forms thereof | |
| DK3720879T3 (da) | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer | |
| IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
| DK3349731T3 (da) | Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft | |
| DK3897697T3 (da) | Peptider til behandling og forebyggelse af diabetes og forbundne lidelser | |
| DK3630112T3 (da) | Kombination af regorafenib og nivolumab til behandling af cancer | |
| DK3290436T3 (da) | Phenylalanin-fri protein til behandlingen af pku | |
| DK3862015T3 (da) | Peptider til anvendelse ved behandling af inflammatorisk colitis | |
| DK3618853T3 (da) | Fibrinogen-gamma-prime-varianter til anvendelse til behandling af en infektion | |
| GB201821207D0 (en) | Immunotherapy therapy | |
| DK3429625T3 (da) | Fremgangsmåde til behandling af fedme | |
| PT4021487T (pt) | Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b | |
| DK4061299T3 (da) | Indretning til behandling af cellulitis | |
| DK4073051T3 (da) | Fremgangsmåde og mellemstof til fremstilling af oxetan-2-ylmethanamin | |
| IL292599A (en) | tmem219 antibodies and medical uses thereof | |
| DK3568146T3 (da) | Planteekstrakt til forebyggelse og behandling af hårtab |